Last updated: February 15, 2026
What Is NDC 72305-0200?
NDC 72305-0200 refers to a specific drug product identified in the National Drug Code (NDC) system. According to available data, this NDC corresponds to Insulin Aspart (Fiasp), marketed by Novo Nordisk. It is a rapid-acting insulin used for diabetes management, typically administered via pen-injector or vial.
Market Size and Trends
Global Insulin Market (2022–2027)
-
Estimated worth: $50 billion in 2022
-
Compound Annual Growth Rate (CAGR): 5% to 7%
-
Drivers:
-
Rising incidence of diabetes, projected to reach 537 million adults globally by 2030[1].
-
Preference for rapid-acting insulins over traditional options.
-
Advances in delivery devices and formulations.
-
Major markets: U.S., Europe, China, Japan.
Insulin Aspart-Specific Data
Competitive Landscape
-
Key competitors: Humalog (Eli Lilly), NovoLog (Novo Nordisk), Apidra (Sanofi).
-
Fiasp's differentiation: Faster onset of action.
Price Points and Historical Data
Historical Pricing (U.S. Market)
Pricing Trends (2022–2023)
-
Price increases of approximately 6%–8% in 2022.
-
Post-expiry of exclusive patent protections in some markets, biosimilars may enter at 30%–50% lower prices.
Cost Factors
Price Projections (2024–2028)
Market Entry of Biosimilars
- Biosimilars for insulin aspart are expected to launch by 2025–2026, potentially reducing prices.
Projected Price Trends
| Year |
Estimated Per-Dose Price |
Notes |
| 2024 |
$180–$220 |
Continued brand pricing with minor increases, limited biosimilar competition. |
| 2025 |
$150–$200 |
Entry of biosimilars beginning, lowering overall prices. |
| 2026 |
$130–$180 |
Increased biosimilar presence, pricing pressure intensifies. |
| 2027 |
$120–$170 |
Market stabilizes; biosimilar adoption reaches 50%. |
| 2028 |
$120–$160 |
Price plateau; discounts in high-volume healthcare settings. |
Key Assumptions
- Biosimilar adoption accelerates due to regulatory approvals and pricing incentives.
- Reimbursement policies favor lower-cost biosimilars.
- Patent exclusivity for Fiasp remains until at least 2025, influencing pricing stability until then.
Regulatory and Policy Impact
- The U.S. FDA approved biosimilar versions of insulin aspart, including Lyumjev (Eli Lilly) in 2023, with anticipated market entry by 2025.
- European Medicines Agency (EMA) also approved biosimilars, fostering price competition.
Impact on Pricing
- Biosimilar entry typically results in a 10%–50% reduction in influencer product prices.
- Reimbursement policies and insurance formularies significantly influence out-of-pocket costs for patients.
Conclusion
The market for insulin aspart (including NDC 72305-0200) is expanding driven by increasing diabetes prevalence and technological innovation. Price projections indicate gradual declines beginning around 2025, with biosimilar competition being a significant driver. Wholesale and consumer prices are expected to stabilize at lower levels post-biosimilar entry.
Key Takeaways
- The global insulin market grows at 5%–7% annually, with rapid-acting insulins gaining market share.
- Current U.S. per-dose costs are approximately $180–$220; overall annual patient costs range from $7,000 to $9,000.
- Biosimilar entry slated for 2025–2026 will likely reduce prices by 30%–50%.
- Market dynamics, patent protections, and regulatory approvals significantly influence pricing trends.
FAQs
1. When will biosimilars for insulin aspart enter the market?
Expected by 2025–2026, following regulatory approvals and patent expirations.
2. How much are insulin aspart products currently costing?
Per-dose prices hover around $180–$220, with annual patient costs between $7,000 and $9,000.
3. What factors impact insulin pricing the most?
Manufacturing costs, patent protections, insurance reimbursement policies, and market competition.
4. Will biosimilars completely replace brand-name insulins?
Not immediately; adoption depends on regulatory approval, physician acceptance, and insurance coverage.
5. How is the market expected to evolve over the next five years?
Prices will likely decline gradually post-biosimilar entry, with increased competition driving costs down.
References
[1] International Diabetes Federation. "IDF Diabetes Atlas, 10th Edition," 2022.
